{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-004799","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2022-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.457494+00:00","generated_at":"2026-06-27T07:32:10.357692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M","bullets":["Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.","Net loss $7.34M ($0.15/share); adjusted net loss $6.0M ($0.12/share) excluding $1.34M derivative expenses.","Cash position of $16.8M at quarter-end is the highest ever; completed $12M non-dilutive debt financing.","FDA clearance of Biotres expands TAM from $1B to $5.7B; Bioheart direct-to-consumer launched at $199.","Company reiterates expectation for full-year triple-digit revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-004799","json":"https://secwatch.observer/filing/0001493152-22-004799.json","markdown":"https://secwatch.observer/filing/0001493152-22-004799.md","text":"https://secwatch.observer/filing/0001493152-22-004799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/0001493152-22-004799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222004799/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:32:10.357692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}